Compare Repligen Corporation Common Stock (RGEN) vs TC Energy Corporation Common Stock (TRP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TC Energy Corporation Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while TC Energy Corporation Common Stock trades at $60.84 (market cap $63.97B). The key difference: TC Energy Corporation Common Stock is far larger — about 5.7× Repligen Corporation Common Stock's market cap, and TC Energy Corporation Common Stock pays a 4.02% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TC Energy Corporation Common Stock for 6 Days on average.
| RGEN | TRP | |
|---|---|---|
Market Cap | $11.14B | $63.97B |
Volume | 1,259,263 | 3,039,280 |
Sector | Health | Energy |
52-Week High | $194.57 | $70.91 |
52-Week Low | $102.87 | $49.79 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $108.73B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TRP trades at $61.55, up 1.63% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with $15.24B revenue, 22.91% net margin, and consistent EBITDA growth. Recent developments include Coastal GasLink Phase 2 expansion approval and a $400M pipeline divestiture, positioning for long-term natural gas demand growth. Analyst consensus is strongly bullish with a $85 price target representing 38% upside potential.
TRP presents a compelling investment case with strong profitability, strategic growth initiatives, and overwhelming analyst support. Key risks include execution challenges on major projects, interest rate sensitivity, and energy market volatility. The stock's current valuation at 25x P/E appears reasonable given growth prospects and 4.3% dividend yield, though technical indicators suggest near-term consolidation may occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TC Energy Corporation Common Stock
TC Energy operates energy infrastructure, including natural gas pipelines and storage systems. Its assets transport energy across North America.
Read more on TRP →
